Biosimilars work like established therapeutic agents but have some dissimilarities based on differences in production. These agents should be less expensive than, but as effective as, their patented relatives, but several barriers keep the advantage from being realized.
No takes yet. Share an insight, caveat, or question.
Lyman et al. (2018) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: